NURIX THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.95 USD | -0.21% |
|
+9.58% | +35.17% |
| 12/04 | Sector Update: Health Care Stocks Steady Pre-Bell Friday | MT |
| 12/04 | Sector Update: Health Care | MT |
Valuation
| Fiscal Period: November | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,656 | 1,286 | 584.2 | 301.7 | 827.5 | - | - |
| Enterprise Value (EV) 1 | 1,656 | 990 | 223.1 | 13.79 | 530.9 | 530.7 | 713.1 |
| P/E ratio | -15.4 x | -10.6 x | -3.34 x | -2.35 x | -4.68 x | -4.18 x | -4.01 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 92.9 x | 43.2 x | 15.1 x | 3.92 x | 11.6 x | 12.4 x | 10.8 x |
| EV / Revenue | 92.9 x | 33.3 x | 5.78 x | 0.18 x | 7.45 x | 7.94 x | 9.28 x |
| EV / EBITDA | -26.4 x | -8.6 x | -1.25 x | -0.09 x | -3.5 x | -3.13 x | -3.92 x |
| EV / FCF | -357 x | -11 x | -1.3 x | -0.15 x | -3.12 x | -2.06 x | -2.66 x |
| FCF Yield | -0.28% | -9.09% | -77.1% | -651% | -32% | -48.4% | -37.6% |
| Price to Book | 5.71 x | 3.76 x | 1.92 x | 1.51 x | 3.01 x | 4.08 x | 7.24 x |
| Nbr of stocks (in thousands) | 38,855 | 44,613 | 47,148 | 48,504 | 59,317 | - | - |
| Reference price 2 | 42.62 | 28.82 | 12.39 | 6.220 | 13.95 | 13.95 | 13.95 |
| Announcement Date | 16/02/21 | 27/01/22 | 09/02/23 | 15/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: November | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 31.12 | 17.82 | 29.75 | 38.63 | 76.99 | 71.27 | 66.83 | 76.86 |
| EBITDA 1 | - | -62.8 | -115.1 | -178.5 | -147.5 | -151.7 | -169.8 | -181.7 |
| EBIT 1 | - | -64.98 | -117.9 | -183.9 | -155.1 | -182.9 | -218.9 | -246.5 |
| Operating Margin | - | -364.66% | -396.26% | -476.01% | -201.41% | -256.67% | -327.59% | -320.73% |
| Earnings before Tax (EBT) 1 | - | -63.78 | -117.1 | -180.4 | -143.9 | -170.7 | -221.4 | -253.2 |
| Net income 1 | - | -43.24 | -117.2 | -180.4 | -143.9 | -170.8 | -221.3 | -253.2 |
| Net margin | - | -242.66% | -393.93% | -466.93% | -186.98% | -239.6% | -331.2% | -329.44% |
| EPS 2 | -2.200 | -2.760 | -2.730 | -3.710 | -2.650 | -2.978 | -3.338 | -3.482 |
| Free Cash Flow 1 | - | -4.633 | -90.03 | -172 | -89.77 | -170 | -257 | -268 |
| FCF margin | - | -26% | -302.61% | -445.41% | -116.6% | -238.53% | -384.55% | -348.67% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 05/05/20 | 16/02/21 | 27/01/22 | 09/02/23 | 15/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: November | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.396 | 9.621 | 11.43 | 10.79 | 6.783 | 12.68 | 30.68 | 18.47 | 15.16 | 16.58 | 21.78 | 17.46 | 16.8 | 16.88 | 16.88 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -37.95 | -42.74 | -45.72 | -46.72 | -48.69 | -42.95 | -26.76 | -40.01 | -45.33 | -45.22 | -42.09 | -47.38 | -50.76 | -49.17 | -49.17 |
| Operating Margin | -513.16% | -444.28% | -399.89% | -432.93% | -717.82% | -338.6% | -87.25% | -216.67% | -299.06% | -272.65% | -193.23% | -271.3% | -302.21% | -291.39% | -291.39% |
| Earnings before Tax (EBT) 1 | -37.66 | -42.53 | -45.4 | -45.71 | -46.72 | -40.73 | -24.28 | -36.98 | -41.96 | -41.43 | -39.18 | -44.44 | -47.67 | -48.17 | -48.42 |
| Net income 1 | -37.7 | -42.53 | -45.4 | -45.71 | -46.72 | -40.73 | -24.28 | -36.98 | -41.96 | -41.52 | -39.19 | -44.45 | -47.68 | -48.17 | -48.42 |
| Net margin | -509.76% | -442.09% | -397.14% | -423.58% | -688.74% | -321.11% | -79.14% | -200.26% | -276.77% | -250.33% | -179.88% | -254.54% | -283.87% | -285.46% | -286.95% |
| EPS 2 | -0.8500 | -0.9500 | -1.010 | -0.9000 | -0.8600 | -0.7500 | -0.4500 | -0.6800 | -0.7700 | -0.7600 | -0.6951 | -0.7529 | -0.7696 | -0.7750 | -0.7800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 27/01/22 | 08/04/22 | 07/07/22 | 06/10/22 | 09/02/23 | 13/04/23 | 13/07/23 | 12/10/23 | 15/02/24 | 10/04/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: November | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 296 | 361 | 288 | 297 | 297 | 114 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -4.63 | -90 | -172 | -89.8 | -170 | -257 | -268 |
| ROE (net income / shareholders' equity) | - | -37.2% | -37.1% | -55.8% | -57.1% | -78.9% | -106% | -172% |
| ROA (Net income/ Total Assets) | - | -19.6% | -26.8% | -25.7% | -37.3% | -51.2% | -82% | -102% |
| Assets 1 | - | 220.2 | 436.6 | 701.2 | 386.2 | 333.8 | 269.8 | 248.4 |
| Book Value Per Share 2 | - | 7.470 | 7.660 | 6.440 | 4.120 | 4.630 | 3.420 | 1.930 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | 4.55 | 5.66 | 12.2 | 8.4 | 9 | 9.5 | 10 |
| Capex / Sales | - | 25.55% | 19.03% | 31.69% | 10.91% | 12.63% | 14.21% | 13.01% |
| Announcement Date | 05/05/20 | 16/02/21 | 27/01/22 | 09/02/23 | 15/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
13.95
USD
Average target price
25.09
USD
Spread / Average Target
+79.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +35.17% | 827M | |
| +2.97% | 108B | |
| +10.21% | 104B | |
| +2.59% | 22.33B | |
| -12.77% | 22.19B | |
| -7.05% | 18.69B | |
| -37.64% | 17.74B | |
| -6.50% | 17.64B | |
| +6.00% | 14.05B | |
| +37.20% | 12.51B |
- Stock Market
- Equities
- NRIX Stock
- Financials Nurix Therapeutics, Inc.